What Is CPS 1 Deficiency? Causes, Symptoms, and Treatment

CPS1 deficiency is a rare inherited disorder in which the body cannot properly remove nitrogen waste from the blood, leading to dangerous buildups of ammonia. It is caused by mutations in the gene that produces carbamoyl phosphate synthetase 1, the enzyme responsible for kickstarting the urea cycle in the liver. With an estimated incidence of roughly 1 in 1,300,000 in the United States, it ranks among the rarest and most severe of the urea cycle disorders, and its consequences range from life-threatening neonatal crises to subtler problems that surface years or even decades later.¹

What the CPS1 Enzyme Actually Does

Your body breaks down protein constantly, whether from food or from its own tissues during normal turnover. That process generates ammonia, a nitrogen-containing compound that is toxic to the brain and other organs even in small excess. The liver’s urea cycle exists to capture that ammonia and convert it into urea, a harmless substance you excrete in urine. CPS1 is the very first enzyme in that cycle. Working inside the mitochondria of liver cells, it combines ammonia with bicarbonate to form a molecule called carbamoyl phosphate, which then feeds into the rest of the cycle.² Because CPS1 is the rate-limiting step, a bottleneck that sets the pace for the entire cycle, any significant loss of its activity stalls nitrogen disposal at the very start.³

CPS1 does not work alone. It needs an activator molecule called N-acetylglutamate (NAG) to switch it on, along with magnesium and ATP for energy.⁴ This dependence on NAG becomes clinically relevant when considering targeted treatments, as we will see later. When CPS1 is absent or barely functional, ammonia accumulates in the bloodstream. High ammonia is directly toxic to brain cells, causing swelling in astrocytes (the support cells in the brain) through a cascade involving oxidative stress and disruption of mitochondrial function.⁵ That brain swelling is the central danger in every ammonia crisis.

How CPS1 Deficiency Is Inherited

CPS1 deficiency follows an autosomal recessive pattern, meaning a child must inherit a faulty copy of the CPS1 gene from each parent to develop the disease. The CPS1 gene sits on chromosome 2. Carriers, people with one working copy and one faulty copy, typically show no symptoms because one functional gene produces enough enzyme to keep the urea cycle running.¹ When both parents are carriers, each pregnancy carries a one-in-four chance of producing an affected child.

Prevalence varies by country. In the United States, the estimated prevalence is about 1 in 975,000. In Japan, it is roughly 1 in 800,000, and in Finland, about 1 in 539,000.¹ These numbers make it one of the rarest urea cycle disorders, far less common than ornithine transcarbamylase deficiency, the most frequently diagnosed type. The rarity itself creates a challenge: many physicians will never encounter a case, which can lead to delayed diagnosis.

Symptoms in Newborns

About half of all patients with urea cycle disorders present in the newborn period.⁶ Neonatal-onset CPS1 deficiency is particularly severe. Babies are usually born appearing healthy, but as they begin feeding and taking in protein, ammonia levels climb rapidly. Within days, sometimes hours, a cascade of worsening symptoms develops:⁷

Feeding problems: the baby refuses to eat or vomits frequently.
Excessive sleepiness: the infant becomes increasingly difficult to rouse.
Low muscle tone: the baby feels floppy when picked up.
Low body temperature: hypothermia that does not respond well to warming.
Seizures and breathing problems: as ammonia continues to rise, the brain becomes more severely affected.
Coma: without urgent treatment, the crisis can progress to coma and death.

A frequent and dangerous complication of neonatal-onset disease is misdiagnosis. Because the early symptoms, poor feeding, lethargy, and low temperature, overlap with common neonatal infections like sepsis, CPS1 deficiency is often initially treated as an infection. In one Malaysian series, all patients were initially diagnosed with infections before anyone checked ammonia levels.⁸ That delay can be fatal. The single most important step in catching neonatal urea cycle disorders is simply thinking to measure ammonia in a sick newborn whose symptoms do not improve with antibiotics.

Late-Onset and Adult Cases

Not everyone with CPS1 deficiency gets sick in the first days of life. Some patients retain enough residual enzyme activity to manage nitrogen waste under normal conditions. These individuals may go months, years, or even decades before anything goes wrong. A trigger, often something that increases the body’s protein breakdown or ammonia load, can push them into their first crisis. Known triggers include infections with high fevers, surgery, prolonged fasting, rapid weight loss, certain medications, or unusually high protein intake.

In a striking example, a 59-year-old Japanese woman was diagnosed with CPS1 deficiency after she received steroid treatment for an unrelated muscle inflammation condition. She suddenly developed confusion that progressed to coma, with ammonia levels climbing to extreme levels. Genetic testing revealed she was homozygous for a pathogenic variant in the CPS1 gene, meaning she had carried the condition her entire life without a crisis severe enough to trigger investigation.⁹ Cases like this underscore that CPS1 deficiency is not exclusively a pediatric disease. Adults with unexplained confusion, recurrent vomiting, or episodes of altered consciousness should have ammonia checked, particularly if they are receiving medications known to stress liver metabolism.

How CPS1 Deficiency Is Diagnosed

The first and most urgent clue is a high ammonia level in the blood. If ammonia is elevated, doctors typically order a plasma amino acid profile. In CPS1 deficiency, citrulline and arginine are markedly low because the urea cycle stalls before citrulline can be produced. At the same time, glutamine and alanine climb because the body tries to store excess nitrogen in these amino acids.¹⁰ That specific pattern, low citrulline combined with high glutamine, points strongly toward either CPS1 deficiency or a deficiency of its activator enzyme, NAGS.

Distinguishing CPS1 deficiency from other urea cycle disorders requires additional steps. Measuring urinary orotic acid helps separate it from ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder, which shares a similar amino acid pattern but causes orotic acid to rise. In CPS1 deficiency, orotic acid stays normal or low.¹¹ Genetic sequencing of the CPS1 gene provides the definitive diagnosis and identifies the specific mutations involved, which can be important for predicting severity and guiding treatment choices.

Newborn screening programs in most countries do not directly screen for CPS1 deficiency. Standard screening panels measure citrulline and can flag it when levels are very low, but detection rates remain limited. Adding orotic acid measurement to newborn screening panels has been proposed as a way to improve sensitivity and help differentiate between types of urea cycle disorders.¹¹

Emergency Treatment for Ammonia Crises

When ammonia levels spike, treatment is a race against brain damage. The immediate goals are to stop ammonia production and remove ammonia from the blood as fast as possible. In practice, this means halting all protein intake temporarily, providing high-calorie intravenous fluids (usually glucose with lipids) to prevent the body from breaking down its own muscle for energy, and starting ammonia-scavenging medications.

Ammonia scavengers work by offering the body alternative routes to get rid of nitrogen that bypass the broken urea cycle. Sodium benzoate binds to the amino acid glycine, and sodium phenylacetate (or its prodrug, phenylbutyrate) binds to glutamine. Both create compounds that the kidneys can excrete, pulling nitrogen out of the body without needing the urea cycle at all.¹² If ammonia levels are dangerously high and not dropping quickly enough with medications alone, hemodialysis can rapidly clear ammonia from the blood.

Long-Term Management

Between crises, the day-to-day management of CPS1 deficiency revolves around keeping ammonia levels within a safe range. Diet is the cornerstone. Because protein is the main dietary source of nitrogen, patients follow a carefully controlled low-protein diet. The goal is to provide just enough protein for growth and tissue maintenance without overwhelming the limited urea cycle capacity. Specialized medical formulas that provide essential amino acids without excess nitrogen are commonly used, especially in infants and young children.¹ Monitoring blood levels of amino acids and ammonia regularly, and adjusting protein intake accordingly, is essential throughout life.

Most patients also take ammonia-scavenging medications daily, not just during crises. Sodium phenylbutyrate and glycerol phenylbutyrate are the most commonly prescribed. These drugs reduce the baseline nitrogen load so the remaining urea cycle capacity can cope. Despite their effectiveness, these medications come with real quality-of-life costs. They taste terrible, require precise dosing schedules, and can cause nausea and body odor. Caregivers of children with urea cycle disorders have described the daily medication routine as one of the most stressful aspects of the condition, with some resorting to administering doses in tiny amounts throughout the day because the child cannot tolerate the taste.¹³

Carglumic Acid as a Targeted Therapy

Carglumic acid (also called N-carbamylglutamate) is a synthetic version of NAG, the molecule CPS1 needs to become active. It was originally developed for NAGS deficiency, a condition where the body cannot make enough NAG. The logic of trying it in CPS1 deficiency is straightforward: if a patient’s CPS1 enzyme is present but underperforming, flooding the system with extra activator might coax more activity out of whatever enzyme remains.

The reality is more complicated. Whether carglumic acid helps depends heavily on the specific mutations involved. Some CPS1 mutations reduce the enzyme’s stability or weaken its ability to bind NAG. In those cases, carglumic acid can improve enzyme function by saturating the activator binding sites and even protecting the fragile enzyme from degradation. In one cohort study, most patients who received carglumic acid appeared to benefit in terms of survival and metabolic control. But in patients whose mutations prevent any functional CPS1 protein from being made at all, carglumic acid has nothing to activate and provides no benefit. Worse, in certain variants, carglumic acid may actually compete with the body’s own NAG and reduce whatever residual urea cycle function exists.¹⁴ This makes genetic testing more than an academic exercise. Knowing the exact mutation helps doctors predict whether carglumic acid is worth trying.¹⁵

Liver Transplantation

Because CPS1 is expressed almost exclusively in the liver, replacing the liver replaces the enzyme. Liver transplantation is currently the only cure for CPS1 deficiency, in the sense that it resolves the underlying metabolic problem. After a successful transplant, patients typically achieve normal ammonia levels, can eat a normal diet, and no longer need ammonia-scavenging medications.¹⁶

Living-donor transplantation is an option, and the donor can even be a carrier parent. Although a carrier’s liver produces somewhat less CPS1 than a non-carrier’s, it produces enough for normal function. Studies of living-donor liver transplants from heterozygous (carrier) parents to affected children have shown that recipients achieved full resolution of their metabolic problems, with no complications for the donors.¹⁶ Transplantation has also been successful in adults. The 59-year-old woman diagnosed during steroid treatment underwent a living-donor liver transplant and was subsequently cured.¹⁷

Transplantation is not without downsides. It is major surgery, requires lifelong immunosuppression to prevent organ rejection, and carries its own risks of infection and complications. Donor organ availability is limited. For neonatal-onset patients, the question of timing is difficult: transplanting too early risks operating on a very small, very sick infant, while waiting too long risks more ammonia-related brain damage. Many centers aim to stabilize the child medically, get through the first months, and then transplant before repeated crises accumulate neurological harm.

Gene Therapy Research

The prospect of gene therapy for CPS1 deficiency is especially appealing because the disease is caused by loss of a single enzyme in a single organ. In theory, delivering a working copy of the CPS1 gene to liver cells could restore the urea cycle without the need for transplant surgery or immunosuppression. In practice, there is a significant technical hurdle: the CPS1 gene’s coding sequence is large, around 4,500 base pairs, which bumps against the packaging limit of adeno-associated virus (AAV) vectors, the most commonly used delivery vehicles for liver-targeted gene therapy.

Researchers have tackled this problem with two creative approaches. One team developed a split-vector strategy, dividing the CPS1 gene and its regulatory elements across two separate AAV particles that recombine inside the cell after delivery. In mice engineered to lack CPS1, this dual-vector approach produced long-term survival, improved ammonia levels, restored amino acid balance, and generated measurable CPS1 enzyme activity in the liver.¹⁸ Another group took a different approach, using a single oversized AAV8 vector with a compact regulatory cassette to squeeze the CPS1 gene into one particle. Treated mice survived to the study’s end at nine months with controlled ammonia, while untreated mice all died of severe hyperammonemia.¹⁹

Both strategies are still in preclinical stages, tested only in mice so far. The jump from mouse to human is significant, involving questions about immune reactions to the vector, durability of the gene expression over a full human lifespan, and whether the approach works as well in a much larger liver. But the proof of concept is solid, and for a disease with so few treatment options, these results have generated genuine optimism in the metabolic disease community.

Prenatal Testing and Family Planning

For families who already have a child with CPS1 deficiency, prenatal diagnosis is available and well established. Once the specific mutations in the family are identified through genetic sequencing, those mutations can be tested for in a future pregnancy using chorionic villus sampling as early as the first trimester.²⁰ Amniocentesis is another option slightly later in pregnancy.²¹ Preimplantation genetic testing, where embryos created through IVF are screened before transfer, is another path available in many fertility centers.

Genetic counseling is strongly recommended for carrier couples. Because the condition is autosomal recessive, carrier parents face a 25 percent chance of an affected child, a 50 percent chance of a carrier child, and a 25 percent chance of an unaffected non-carrier child with each pregnancy. Carrier testing for extended family members can also be informative, particularly in communities where consanguinity (marriage between relatives) is more common, which increases the likelihood of both parents carrying the same rare mutation.

The Emotional and Practical Weight on Families

Numbers and biochemistry only tell part of the story. Living with CPS1 deficiency, or caring for a child who has it, involves a constant undercurrent of vigilance that few other conditions demand. Every illness, every missed meal, every bout of vomiting becomes a potential trigger for a metabolic crisis. Caregivers of children with urea cycle disorders have described feeling like they live “on a knife’s edge,” never fully able to relax.¹³

The dietary restrictions are socially isolating, especially for older children and teenagers. Birthday parties, school lunches, and eating out with friends all require planning or compromise. Medication schedules are rigid, often involving doses timed around the clock. Research on families dealing with inherited metabolic diseases shows that caregiver burden and how severe the parents perceive the disease to be are the strongest predictors of quality-of-life scores for both the child and the family, more so than the specific diagnosis or whether the disease had an acute or gradual onset.²² Access to metabolic disease specialists, dietitians experienced with urea cycle disorders, and psychosocial support services can make a meaningful difference. Many families also find value in connecting with patient advocacy organizations, where shared experience with other families navigating the same challenges offers a kind of practical and emotional support that clinical teams alone cannot provide.

Neurological outcomes remain the hardest part to predict. Children who survive neonatal crises with ammonia levels that stayed below a certain threshold for a relatively short time may develop normally. Others who experienced prolonged or repeated severe hyperammonemia may face intellectual disability, learning difficulties, or movement disorders. This uncertainty, combined with the constant threat of another crisis, makes early and aggressive treatment not just medically important but profoundly consequential for a child’s long-term cognitive and developmental trajectory.

1
PubMed Central. Carbamoly-phosphate synthetase 1 (CPS1) deficiency: A tertiary center retrospective cohort study and literature review
2
PubMed. Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency
3
PubMed Central. CPS1: Looking at an ancient enzyme in a modern light
4
PubMed Central. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment
5
PubMed. Mechanisms of ammonia-induced astrocyte swelling
6
PubMed Central. Suggested guidelines for the diagnosis and management of urea cycle disorders
7
PubMed Central. Neonatal-onset carbamoyl phosphate synthetase I deficiency
8
PubMed. Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients
9
Molecular Genetics and Metabolism Reports. Carbamoyl phosphate synthetase 1 deficiency manifested in an adult treated with prednisone for polymyositis, and cured by live-donor liver transplantation
10
PubMed Central. A constitutive knockout of murine carbamoyl phosphate synthetase 1 results in death with marked hyperglutaminemia and hyperammonemia
11
PubMed. The role of orotic acid measurement in routine newborn screening for urea cycle disorders
12
PubMed Central. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease
13
PubMed Central. The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study
14
Molecular Genetics and Metabolism Reports. Carbamoly-phosphate synthetase 1 (CPS1) deficiency: A tertiary center retrospective cohort study and literature review
15
PubMed. Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder
16
PubMed. Living-donor liver transplantation for carbamoyl phosphate synthetase 1 deficiency
17
PubMed. Late-onset carbamoyl phosphate synthetase 1 deficiency in an adult cured by liver transplantation
18
PubMed Central. Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency
19
Molecular Therapy Nucleic Acids. Use of an oversized AAV8 vector for CPS1 deficiency results in long-term survival and ammonia control
20
PubMed. Prenatal diagnosis of carbamoyl phosphate synthetase I deficiency by identification of a missense mutation in CPS1
21
PubMed. Successful prenatal molecular diagnosis of carbamyl-phosphate synthetase I deficiency in two at-risk pregnancies
22
PubMed Central. Caregiver burden, and parents’ perception of disease severity determine health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism